ANDA 200290, held by Ipca Laboratories. Losartan Potassium.
As of Nov 21, 2026, ANDA 200290 (Losartan Potassium), held by Ipca Laboratories, was first approved by FDA on Aug 30, 2013, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 30, 2013 | Original application | Approved | None posted |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Discontinued |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Discontinued |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Discontinued |
| Aug 18, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 1, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 3, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 3, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 13, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 5, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 30, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters